Highlights ViaDerma, Inc.

Equities

VDRM

US92555K1016

Market Closed - OTC Markets Other stock markets 20:57:04 30/05/2024 BST			5-day change	1st Jan Change
0.00675 ^USD	-3.57%		+3.03%	-35.85%

2023	ViaDerma, Inc. Announces FDA Registration Application Update & Brand Name for New Hair Regrowth Product	CI
2023	ViaDerma Announces Intent to Launch New Minoxidil Hair Regrowth Product	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

ViaDerma, Inc. Announces FDA Registration Application Update & Brand Name for New Hair Regrowth Product	16/03/23	CI
ViaDerma Announces Intent to Launch New Minoxidil Hair Regrowth Product	08/03/23	CI
ViaDerma, Inc. Successfully Completes Quality Control Testing of Its New Vitastem Products	15/09/22	CI
ViaDerma, Inc. Set to Launch Two New and Improved Versions of Its Flagship Product, Vitastem and Vitastem Ultra	04/10/21	CI
ViaDerma, Inc. Provides Updates on Current Business Activities	24/06/21	CI
ViaDerma, Inc. Announces Expansion of Its Current Licensing Agreement	02/06/21	CI
ViaDerma, Inc. Nearing Initial Order from Large Hospital Network	13/05/21	CI
ViaDerma, Inc. Provides Revenue Guidance for the First Quarter of 2021	08/04/21	CI
ViaDerma, Inc. Completes a Licensing Agreement with a Group of Affiliate Wound Care Medical Practices Operating in Six States	21/01/21	CI
ViaDerma, Inc. Enters into A $250,000 Initial Sales Agreement with Vage Nigeria Ltd	24/04/18	CI
ViaDerma, Inc. Grants Approval to sell VitaStem(TM) its FDA Registered Topical Antibiotic on Amazon.com and Expands Testing into Major US Hospital Chains to Ramp Up Domestic Sales & Begins Production of New Products	21/11/17	CI
ViaDerma, Inc. Commences Distribution of VitaStem(TM), its FDA Registered Topical Antibiotic, and Looks to Expand its Partnership with Biogenx	19/10/17	CI
ViaDerma, Inc. Receives National Drug Code from the FDA for Prolayed	27/06/17	CI
Viaderma, Inc. Receives Positive Results on Phase I Testing in Canada with its Proprietary THC Delivery and Moves to Phase II Trials and Development of New Products with its MMJ Technologies	15/05/17	CI
Viaderma, Inc. Enters the Sexual Dysfunction Market & Files with the Food and Drug Administration for New OTC Drug to Conquer Premature Ejaculation for Men	05/04/17	CI
ViaDerma, Inc. Signs Licensing and Distribution Agreement with Two Pharmaceuticals Companies for its FDA Registered Drug	11/01/17	CI
ViaDerma, Inc. Announces TetraStem	09/12/14	CI
ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA	30/10/14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+201.5% on SUPER MICRO COMPUTER since our purchase on February 17, 2023

Replicate our performance

fermer